Optimal surgical margin for hepatocellular carcinoma following HAIC-based conversion therapy: a target trial emulation study
The oncological necessity of wide surgical margins for hepatocellular carcinoma (HCC) following successful conversion therapy remains an unsettled debate. Extrapolating the conventional 1 cm rule from chemotherapy-naïve populations ignores the unique locoregional sterilization induced by hepatic arterial infusion chemotherapy (HAIC). This study leverages a causal inference framework to delineate the optimal resection extent for this distinct patient cohort. Utilizing a target trial emulation approach, we analyzed observational data from patients undergoing curative R0 resection after HAIC-mediated conversion. The study population was stratified based on margin width greater or less than 1 cm, with baseline confounders balanced via stabilized inverse probability of treatment weighting. We further validated the findings through multiple sensitivity analyses at explicitly labelled alternative thresholds ( ≥ 0.5 cm vs. < 0.5 cm; > 0 cm vs. 0 cm; and 0.1 cm vs. 0 cm) to ensure the stability of our causal conclusions. Analysis of the weighted cohort demonstrated that a narrow resection margin delivered overall survival (OS: HR, 0.96; 95% CI: 0.70–1.31; P = 0.784) and recurrence-free survival (RFS: HR, 0.83; 95% CI: 0.65–1.06; P = 0.136) rates statistically indistinguishable from those achieved with a wide margin. This prognostic equivalence persisted across comprehensive sensitivity testing at varying cut-off values. Exploratory subgroup interactions suggested that extended clearances might offer a survival advantage specifically for high-risk phenotypes. A 1 cm resection margin was not associated with improved OS or RFS after HAIC-based conversion surgery. These findings suggest that a microscopically negative R0 margin may be an adequate surgical endpoint in this setting. These data do not support routine resection beyond a negative R0 margin, and extended resections may instead be reserved for biologically aggressive subtypes.
Authors
- Hao Cai (ORCID: https://orcid.org/0000-0002-1492-4701)
- 陈焕伟
- Rong Guo (ORCID: https://orcid.org/0000-0003-2799-3463)
- Chong Zhong (ORCID: https://orcid.org/0000-0003-4199-0509)
- 陈祖兵
- Yuxiong Qiu
- Wei Qin (ORCID: https://orcid.org/0000-0003-2161-387X)
- Yajun Tang
- Benyi He (ORCID: https://orcid.org/0000-0003-3590-3288)
- Min Deng
- Fengting Lai
- Dong Li
- Di Tang
- Wei Wei
Institutions
- Sun Yat-sen University (CN)
- Shanghai Jiao Tong University (CN)
- The Seventh Affiliated Hospital of Sun Yat-sen University (CN)
- First Affiliated Hospital of Guangzhou University of Chinese Medicine (CN)
- Shanghai First People's Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- State Key Laboratory of Oncology in South China (CN)
Publication Details
- Journal
- BMC Medicine
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1186/s12916-026-05421-7
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00